BACKGROUND β-blockers have been shown to improve survival after traumatic brain injury
(TBI); however, the impact of continuous dosage of β-blockers on cognitive function has not …

Background: In vivo models of traumatic brain injury (TBI) demonstrate increased cerebral
perfusion, decreased cerebral hypoxia, reduced cerebral edema, and improved neurologic …

Traumatic brain injury (TBI) is a leading cause of mortality and morbidity amongst trauma
patients. Its treatment is focused on minimizing progression to secondary injury …

Background: Recent epidemiologic evidence has identified β-blockade as independently
associated with improved survival in patients with isolated traumatic brain injury (TBI) …

Introduction Traumatic brain injury (TBI) can lead to neurocognitive decline, in part due to
phosphorylated tau (p-tau). Whether p-tau accumulation worsens in the setting of …

BACKGROUND Dysautonomia in traumatic brain injury patients may contribute to
secondary injury. We hypothesize that propranolol is the best β-blocker (BB) to block the …

BACKGROUND β-Adrenergic receptor blockers (BBs) administered after trauma blunt the
cascade of immune and inflammatory changes associated with injury. BBs are associated …

Background The purpose of the present study was to determine whether magnolol, a free
radical scavenger, mitigates the deleterious effects of traumatic brain injury (TBI). Material …

Phenoxybenzamine (PBZ) is an FDA approved α-1 adrenergic receptor antagonist that is
currently used to treat symptoms of pheochromocytoma. However, it has not been studied as …

Background Although beta-adrenergic receptor blockade may improve outcomes after
traumatic brain injury (TBI), its early use is not routine. We hypothesize that judicious early …